DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0243114A1 Chen (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0243114A1 Chen (43) Pub US 20160243114A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0243114A1 Chen (43) Pub. Date: Aug. 25, 2016 (54) METHODS OF TREATING CANCERUSING Publication Classification COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERVATIVE (51) Int. Cl. A613 L/495 (2006.01) (71) Applicant: NEONCTECHNOLOGIES INC., Los A63L/045 (2006.01) Angeles, CA (US) A6II 45/06 (2006.01) A647/48 (2006.01) (72) Inventor: Thomas Chen, La Canada, CA (US) (52) U.S. Cl. CPC ............. A6 IK3I/495 (2013.01); A61 K47/481 (21) Appl. No.: 15/026,649 (2013.01); A61 K3I/045 (2013.01); A61 K 45/06 (2013.01) (22) PCT Fled: Oct. 8, 2014 (57) ABSTRACT PCT NO.: PCT/US1.4/596OO (86) A method for treating brain metastases of a cancer in a mam S371 (c)(1), mal includes administering to the mammal atherapeutically (2) Date: Apr. 1, 2016 effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The penllyl alcohol derivative may be Related U.S. Application Data perillyl alcohol conjugated with a therapeutic agent, Such as a chemotherapeutic agent. The chemotherapeutic agents that (63) Continuation of application No. 14/455.293, filed on may be used in the present invention include a DNA alkylat Aug. 8, 2014. ing agent, a topoisomerase inhibitor, an endoplasmic reticu (60) Provisional application No. 61/888.253, filed on Oct. lum stress inducing agent, a platinum compound, an antime 8, 2013. tabolite, an enzyme inhibitor, and a receptor antagonist. Patent Application Publication Aug. 25, 2016 Sheet 1 of 21 US 2016/0243114A1 cytotoxicity of DMC in glioma cells - 48h 100 8 axx U.S. 30 x (EE V 388x2 8 60 2 A s R 20 O 5. 50 O O Concentration uM) Figure 1 10 or cytotoxicity of POH-DMC in glioma cells-48h OO ex: 8.2 -0 O d 50 30 100 Concentration (uM) Figure 2 Patent Application Publication Aug. 25, 2016 Sheet 2 of 21 US 2016/0243114A1 Human glioma cells treated with TMZ for 48h 60 - 40 2-4-w, U-87 a-row A172 wrixo J251 O 50 100 150 200 120 Human glioma cells treated with TMZ-POH for 48h Concentration (uM) Figure 4 Patent Application Publication Aug. 25, 2016 Sheet 3 of 21 US 2016/0243114A1 MTT Assay for Rolipram and POH-Rolipram on glioma A172 cells - 48 h treatment 100 w--Rolipram 6.3. OO --POH-Rolipram 4 O ...w.g...w...w... P.--me wir O 2OO 400 600 300 OOO 100 Concentration (uM) Figure 5 MTT Assay for Rolipram and POH-Rolipram on glioma 120 . U-87 cels - 48 h treatment 100 -- Rolipram 30 ta was owPOH-Rolipram 60 " 8. 40 - 20 -200 O 200 400 600 800 OOO 1200 Concentration (uM) -------- Figure 6 Patent Application Publication Aug. 25, 2016 Sheet 4 of 21 US 2016/0243114A1 MTT Assay for Rolipram and POH-Rolipram on glioma U251 cells - 48h treatment re-Rofipram mir-POH-Rolipram OO O 2OO 400 600 800 1000 12OO Concentration (uM) Figure 7 MTT Assay for Rolipram and POH-Rolipram on glioma 12O N229 cells - 48 h treatment 100 mor-Rolipram : -I-POH-Rotipram 80 40 20 w -20) O 2OO 4OO 600 8OO OOO 1200 Concentration (uM) Figure 8 Patent Application Publication Aug. 25, 2016 Sheet 5 of 21 US 2016/0243114A1 Purified POH Figure 9A Patent Application Publication Aug. 25, 2016 Sheet 6 of 21 US 2016/0243114A1 Average Tumor Growth Over Time 3000 2500 so PBS Control --Purified POH 2 O O O -A-Sigma -x-Butyryl-POH 11 O5 OO OO 500 O Relegate 1 8 13 16 20 23 26 29 32 34 36 .38 40 42 44 46 48 50 53 55 57 59 Treatment Day Figure 9B Patent Application Publication Aug. 25, 2016 Sheet 7 of 21 US 2016/0243114A1 Colony Forming Assay for TMZ and TMZ-POH on TMZ sensitive and resistant glioma cells - 72 hr treatment 120 100s ---- - - {TMZ) 8 se Tr(TP) e is TZ 6 O O D MZ-POH Conjugate (TP) 40 N 2 u251 (TP) - U251 (TMZ) 10 2. 30 40 50 60 Drug (uM) Figure 10 CFA of U251 and U251TR with POH - 72 hr treatment. --O. U251 120 --O-- U25 TR 100 O 2. POH (mM) Figure 11 Patent Application Publication Aug. 25, 2016 Sheet 8 of 21 US 2016/0243114A1 MTT Assay for TMZ-POH on U251, U251TR, and normal Astrocytes-72 hr treatment. 2C-T- - -Q-0--- O----- -:i. -A w 60 stsY------ - 3 & N. --- - s -- | O 20 8 80 OO TMZ-POH (uM) Figure 12 MTT Assay for TMZ-POH on BEC, TUBEC, and Astrocytes - 72 hr treatment. O 20 40 60 8 100 TMZ-POH (uM) Figure 13 Patent Application Publication Aug. 25, 2016 Sheet 9 of 21 US 2016/0243114A1 MTT Assay for TMZ-POH on Glioma Cancer Stem Cell USC-04 - 72 hr treatment. --TMZ-POH -TMZ-- 1OO 20 3OO OO Drug Con'c(uM) Figure 14 MTT Assay for POH on Glioma Cancer Stem Cell USC-04-72 hr treatment. 16 40 2O 100 a. 8) --- 60 s S. - 40 - w 2O O -e-POH O.O O5 O 15 2.O. POH (mM) Figure 15 Patent Application Publication Aug. 25, 2016 Sheet 10 of 21 US 2016/0243114A1 MTT Assay for TMZ-POH on Glioma Cancer Stem Cell USC-02 72 hr treater. 12 O 40 > - TMZ-POH |- TMZ-POH --- O --TMZ *r. O 50 1 OO 50 2OO Drug Con'c (uM) Figure 16 MTT Assay for POH on Glioma Cancer Stem Cell USC-02-72 hr treatent. 40 8 O MO) ' 0 %troxwww.gxw-oxwoxx x O. O.5. O 5 POH (mM) Figure 17 Patent Application Publication Aug. 25, 2016 Sheet 11 of 21 US 2016/0243114A1 Western Blot following TMZ-POH treatment of U251 TMZS and U251-TMZr Cells - 18 hr treatment O 20 40 60 80 100 150 200 TMZ-POHuM) O 20 40 60 80 100 150 200 PARP an aii is one in ele PARP CHOP ACTIN U251-TMZS U251-TMZr Figure 18 Patent Application Publication Aug. 25, 2016 Sheet 12 of 21 US 2016/0243114A1 : | 100 200 300 400 500 C O d L O S 2 s u) 0.001-, w w O 20 40 60 80 1 OO O 250 5OO 750 1000 Concentration uM) Concentration uM Figure 19 Patent Application Publication Aug. 25, 2016 Sheet 13 of 21 US 2016/0243114A1 : 20 30 40 Concentration uM) Figure 20A X Š Š S. S š. & Figure 20B Patent Application Publication Aug. 25, 2016 Sheet 14 of 21 US 2016/0243114A1 Figure 21A MGMT Actin Figure 21B - T-P TMZ O6-BG vh. O 30 5050 20010 500 (uM) MGMT ACtin Figure 21C Patent Application Publication Aug. 25, 2016 Sheet 15 of 21 US 2016/0243114A1 Figure 22A O 1. 231-MGMT-1 231-MGMT-2 : w O.O1 x 2OO 3OO 4OO O 1OO 200 300 400 Concentration uM Concentration uM Figure 22B Patent Application Publication Aug. 25, 2016 Sheet 16 of 21 US 2016/0243114A1 Figure 23A 231 MGMT-1 ecoc<c) ©CDO Figure 23B == --No. MDAMB-468 Figure 23C Patent Application Publication Aug. 25, 2016 Sheet 17 of 21 US 2016/0243114A1 Actin Figure 24A Figure 24B TMZ'Y' poh POH Š: Y-H2AX Figure 24C Actin Figure24D Patent Application Publication Aug. 25, 2016 Sheet 18 of 21 US 2016/0243114A1 C. PARP Actin Figure 25B Patent Application Publication Aug. 25, 2016 Sheet 19 of 21 US 2016/0243114A1 125 3. 1OO S 75 O o 50 O 25 - is 8 S 8 Patent Application Publication Aug. 25, 2016 Sheet 20 of 21 US 2016/0243114A1 Day 43 X107 Figure 27A Patent Application Publication Aug. 25, 2016 Sheet 21 of 21 US 2016/0243114A1 Sssssssss days after tumor implantation Figure 27B US 2016/02431 14 A1 Aug. 25, 2016 METHODS OF TREATING CANCERUSING 0005 Metastasized cancer, such as breast cancer, that has COMPOSITIONS COMPRISING PERILLYL spread to the brain poses a similarly serious therapeutic chal ALCOHOL DERVATIVE lenge as malignant gliomas. This challenge once was a late aspect of disease progression, but increasingly is becoming a CROSS REFERENCE TO RELATED first site of disease progression after otherwise Successful APPLICATIONS treatment of primary tumor and metastases outside the cra nium. Traditional breast cancer therapeutics, such as pacli 0001. This application claims priority to U.S. Provisional taxel or doxorubicin, only reach brain metastases at concen Application No. 61/888.253, filed Oct. 8, 2013. This applica trations that are far lower than needed to be therapeutically tion also relates to U.S. application Ser. No. 14/455.293 filed active. P. R. Lockman, et al. Heterogeneous blood-tumor Aug. 8, 2014, which is a continuation of U.S. application Ser. barrier permeability determines drug efficacy inexperimental No. 13/566,731 filed Aug. 3, 2012, which is a continuation of brain metastases of breast cancer, Clin Cancer Res 16 (2010) International Application No. PCT/US2011/049392 filed 5664-5678. The most critical barrier to effective entry of Aug. 26, 2011, which claims priority to U.S. Provisional chemotherapeutics into the brain is the blood brain barrier Application Nos. 61/377,747 (filed Aug. 27, 2010) and (BBB), and very few anticancer drugs are able to overcome 61/471.402 (filed Apr. 4, 2011). The disclosures of all of these this obstacle. E. Fokas, J. P. Steinbach, C. Rodel, Biology of prior filed applications are incorporated by reference herein brain metastases and novel targeted therapies: time to trans in their entireties.
Load more

Recommended publications
  • Theophylline and Selective PDE Inhibitors As Bronchodilators and Smooth Muscle Relaxants
    Eur Respir J, 1995, 8, 637–642 Copyright ERS Journals Ltd 1995 DOI: 10.1183/09031936.95.08040637 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 SERIES 'THEOPHYLLINE AND PHOSPHODIESTERASE INHIBITORS' Edited by M. Aubier and P.J. Barnes Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants K.F. Rabe, H. Magnussen, G. Dent Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Krankenhaus Grosshansdorf, Zentrum für K.F. Rabe, H. Magnussen, G. Dent. ERS Journals Ltd 1995. Pneumologie und Thoraxchirurgie, LVA ABSTRACT: In addition to its emerging immunomodulatory properties, theophy- Hamburg, Grosshansdorf, Germany. lline is a bronchodilator and also decreases mean pulmonary arterial pressure in vivo. The mechanism of action of this drug remains controversial; adenosine Correspondence: K.F. Rabe Krankenhaus Grosshansdorf antagonism, phosphodiesterase (PDE) inhibition and other actions have been advanced Wöhrendamm 80 to explain its effectiveness in asthma. Cyclic adenosine monophosphate (AMP) and D-22927 Grosshansdorf cyclic guanosine monophosphate (GMP) are involved in the regulation of smooth Germany muscle tone, and the breakdown of these nucleotides is catalysed by multiple PDE isoenzymes. The PDE isoenzymes present in human bronchus and pulmonary artery Keywords: Bronchi have been identified, and the pharmacological actions of inhibitors of these enzy- 3',5'-cyclic-nucleotide phosphodiesterase mes have been investigated. phosphodiesterase inhibitors Human bronchus and pulmonary arteries are relaxed by theophylline and by pulmonary artery selective inhibitors of PDE III, while PDE IV inhibitors also relax precontracted smooth muscle theophylline bronchus and PDE V/I inhibitors relax pulmonary artery. There appears to be some synergy between inhibitors of PDE III and PDE IV in relaxing bronchus, and Received: February 1 1995 a pronounced synergy between PDE III and PDE V inhibitors in relaxing pulmon- Accepted for publication February 1 1995 ary artery.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Anagrelide for Gastrointestinal Stromal Tumor
    Author Manuscript Published OnlineFirst on December 7, 2018; DOI: 10.1158/1078-0432.CCR-18-0815 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Anagrelide for gastrointestinal stromal tumor Olli-Pekka Pulkka1, Yemarshet K. Gebreyohannes2, Agnieszka Wozniak2, John-Patrick Mpindi3, Olli Tynninen4, Katherine Icay5, Alejandra Cervera5, Salla Keskitalo6, Astrid Murumägi3, Evgeny Kulesskiy3, Maria Laaksonen7, Krister Wennerberg3, Markku Varjosalo6, Pirjo Laakkonen8, Rainer Lehtonen5, Sampsa Hautaniemi5, Olli Kallioniemi3, Patrick Schöffski2, Harri Sihto1*, and Heikki Joensuu1,9* 1Laboratory of Molecular Oncology, Research Programs Unit, Translational Cancer Biology, Department of Oncology, University of Helsinki, Helsinki, Finland. 2Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. 3Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland 4Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland. 5Research Programs Unit, Genome-Scale Biology, Medicum and Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. 6Institute of Biotechnology, University of Helsinki, Helsinki, Finland. 7MediSapiens Ltd., Helsinki, Finland 8Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland. 9Comprehensive Cancer Center,
    [Show full text]
  • Rolipram, but Not Siguazodan Or Zaprinast, Inhibits the Excitatory Noncholinergic Neurotransmission in Guinea-Pig Bronchi
    Eur Respir J, 1994, 7, 306–310 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07020306 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi Y. Qian, V. Girard, C.A.E. Martin, M. Molimard, C. Advenier Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neuro- Faculté de Médecine Paris-Ouest Labora- transmission in guinea-pig bronchi. Y. Qian, V. Girard C.A.E. Martin, M. Molimard, toire de Pharmacologie, Paris, France. C. Advenier. ERS Journals Ltd 1994. ABSTRACT: Theophylline has been reported to inhibit excitatory noncholinergic Correspondence: C. Advenier Faculté de Médecine Paris-Ouest but not cholinergic-neurotransmission in guinea-pig bronchi. As theophylline might Laboratoire de Pharmacologie exert this effect through an inhibition of phosphodiesterases (PDE), and since many 15, Rue de l'Ecole de Médecine types of PDE have now been described, the aim of this study was to investigate the F-75270 Paris Cedex 06 effects of three specific inhibitors of PDE on the electrical field stimulation (EFS) France of the guinea-pig isolated main bronchus in vitro. The drugs used were siguazo- dan, rolipram and zaprinast, which specifically inhibit PDE types, III, IV and V, Keywords: C-fibres respectively. neuropeptides Guinea-pig bronchi were stimulated transmurally with biphasic pulses (16 Hz, 1 phosphodiesterase inhibitors ms, 320 mA for 10 s) in the presence of indomethacin 10-6 M and propranolol 10-6 Received: March 11 1993 M. Two successive contractile responses were observed: a rapid cholinergic con- Accepted after revision August 8 1993 traction, followed by a long-lasting contraction due to a local release of neuropep- tides from C-fibre endings.
    [Show full text]
  • Integrated Technologies for the Characterization Of
    Integrated technologies for the characterization of phosphodiesterase (PDE) inhibitors Edmond Massuda, Lisa Fleet, Benjamin Lineberry, Laurel Provencher, Abbie Esterman, Dhanrajan Tiruchinapalli, Faith Gawthrop, Christopher Spence, Rajneesh P. Uzgare, Scott Perschke, Seth Cohen, and Hao Chen. 618.01/XX63 Caliper Life Sciences, a PerkinElmer Company, 7170 Standard Drive, Hanover, Maryland, 21076 USA Abstract Phosphodiesterases (PDEs) are a class of signal transduction enzymes regulating various cellular functions and disease Results Results progressions in a number of central or peripheral nervous system-related disorders. For example, these enzymes are involved in neurological diseases including psychosis in schizophrenia, multiple sclerosis and other neurodegenerative PDE1A PDE1B PDE2A PDE3A PDE3B PDE4A1A PDE4B1 Ki and kinact determination using 3D Fit Model 110 110 110 110 110 100 110 110 100 100 100 Percent of Maximum Activity by Time 100 conditions. Thus, safe and highly selective PDE inhibitors or modulators are becoming an important class of disease 100 90 100 90 90 90 90 90 80 90 80 80 80 80 modifying therapeutic agents. We have developed an integrated platform which includes Caliper LabChip™ microfluidic 80 70 80 70 70 70 70 70 60 70 60 60 60 60 mobility-shift assays measuring fluorescent analogs of cAMP and cGMP in conjunction with a cellular assay 60 60 50 50 50 50 50 50 50 40 40 40 40 characterizing intracellular signal transduction in cells modulated by PDE inhibitors. These technologies are useful in 40 40 40 30 30 30 30 %%
    [Show full text]
  • Three-Dimensional Structures of PDE4D in Complex with Roliprams and Implication on Inhibitor Selectivity
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Structure, Vol. 11, 865–873, July, 2003, 2003 Elsevier Science Ltd. All rights reserved. DOI 10.1016/S0969-2126(03)00123-0 Three-Dimensional Structures of PDE4D in Complex with Roliprams and Implication on Inhibitor Selectivity Qing Huai, Huanchen Wang, Yingjie Sun, 7, and 8 prefer to hydrolyze cAMP, while PDE5, 6, and Hwa-Young Kim, Yudong Liu, and Hengming Ke* 9 are cGMP specific. PDE1, 2, 3, 10, and 11 take both Department of Biochemistry and Biophysics and cAMP and cGMP as their substrates. In the past three Lineberger Comprehensive Cancer Center decades, selective inhibitors against the different PDE The University of North Carolina, Chapel Hill families have been widely studied as cardiotonic agents, Chapel Hill, North Carolina 27599 vasodilators, smooth muscle relaxants, antidepres- sants, antithrombotic compounds, antiasthma com- pounds, and agents for improving cognitive functions Summary such as memory (Reilly and Mohler, 2001; Rotella, 2002; Giembycz, 2000; Souness et al., 2000; Huang et al., Selective inhibitors against the 11 families of cyclic 2001). For example, the PDE5 inhibitor sildenafil (Viagra; nucleotide phosphodiesterases (PDEs) are used to Figure 1) is a drug for male erectile dysfunction, and the treat various human diseases. How the inhibitors se- PDE3 inhibitor cilostamide is a drug for heart diseases. lectively bind the conserved PDE catalytic domains is Selective inhibitors of PDE4 form the largest group of unknown. The crystal structures of the PDE4D2 cata- inhibitors for any PDE family and have been studied as lytic domain in complex with (R)- or (R,S)-rolipram sug- anti-inflammatory drugs targeting asthma and chronic gest that inhibitor selectivity is determined by the obstructive pulmonary disease (COPD) and also as ther- chemical nature of amino acids and subtle conforma- apeutic agents for rheumatoid arthritis, multiple sclero- tional changes of the binding pockets.
    [Show full text]
  • Various Subtypes of Phosphodiesterase Inhibitors Differentially Regulate Pulmonary Vein and Sinoatrial Node Electrical Activities
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 19: 2773-2782, 2020 Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities YUNG‑KUO LIN1,2*, CHEN‑CHUAN CHENG3*, JEN‑HUNG HUANG1,2, YI-ANN CHEN4, YEN-YU LU5, YAO‑CHANG CHEN6, SHIH‑ANN CHEN7 and YI-JEN CHEN1,8 1Department of Internal Medicine, Division of Cardiovascular Medicine, Wan Fang Hospital; 2Department of Internal Medicine, Division of Cardiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11696; 3Division of Cardiology, Chi‑Mei Medical Center, Tainan 71004; 4Division of Nephrology; 5Division of Cardiology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei 22174; 6Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490; 7Heart Rhythm Center and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217; 8Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11696, Taiwan, R.O.C. Received May 16, 2019; Accepted January 9, 2020 DOI: 10.3892/etm.2020.8495 Abstract. Phosphodiesterase (PDE)3-5 are expressed in 20.7±4.6%, respectively. In addition, milrinone (1 and 10 µM) cardiac tissue and play critical roles in the pathogenesis of induced the occurrence of triggered activity (0/8 vs. 5/8; heart failure and atrial fibrillation. PDE inhibitors are widely P<0.005) in PVs. Rolipram increased PV spontaneous activity used in the clinic, but their effects on the electrical activity by 7.5±1.3‑9.5±4.0%, although this was not significant, and did of the heart are not well understood. The aim of the present not alter SAN spontaneous activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0208029 A1 Barlow Et Al
    US 20070208029A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0208029 A1 Barlow et al. (43) Pub. Date: Sep. 6, 2007 (54) MODULATION OF NEUROGENESIS BY PDE Related U.S. Application Data INHIBITION (60) Provisional application No. 60/729,366, filed on Oct. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); 21, 2005. Provisional application No. 60/784,605, Todd A. Carter, San Diego, CA (US); filed on Mar. 21, 2006. Provisional application No. Kym I. Lorrain, San Diego, CA (US); 60/807,594, filed on Jul. 17, 2006. Jammieson C. Pires, San Diego, CA (US); Kai Treuner, San Diego, CA Publication Classification (US) (51) Int. Cl. A6II 3 L/506 (2006.01) Correspondence Address: A6II 3 L/40 (2006.01) TOWNSEND AND TOWNSEND AND CREW, A6II 3/4I (2006.01) LLP (52) U.S. Cl. .............. 514/252.15: 514/252.16; 514/381: TWO EMBARCADERO CENTER 514/649; 514/423: 514/424 EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) The instant disclosure describes methods for treating dis eases and conditions of the central and peripheral nervous (73) Assignee: BrainCells, Inc., San Diego, CA (US) system by stimulating or increasing neurogenesis. The dis closure includes compositions and methods based on use of (21) Appl. No.: 11/551,667 a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the forma (22) Filed: Oct. 20, 2006 tion of new nerve cells. Patent Application Publication Sep. 6, 2007 Sheet 1 of 6 US 2007/0208029 A1 Figure 1: Human Neurogenesis Assay: budilast + Captopril Neuronal Differentiation budilast + Captopril ' ' ' 'Captopril " " " 'budilast 10 Captopril Concentration 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 10-40 ammammam 10-9.0 10-8.5 10-8-0 10-75 10-7.0 10-6.5 10-6.0 10-5.5 10-50 10-4.5 Conc (M) Ibudilast Concentration Patent Application Publication Sep.
    [Show full text]
  • Structural Basis for the Activity of Drugs That Inhibit Phosphodiesterases
    Structure, Vol. 12, 2233–2247, December, 2004, ©2004 Elsevier Ltd. All rights reserved. DOI 10.1016/j.str.2004.10.004 Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases Graeme L. Card,1 Bruce P. England,1 a myriad of physiological processes, such as immune Yoshihisa Suzuki,1 Daniel Fong,1 Ben Powell,1 responses, cardiac and smooth muscle contraction, vi- Byunghun Lee,1 Catherine Luu,1 sual response, glycogenolysis, platelet aggregation, ion Maryam Tabrizizad,1 Sam Gillette,1 channel conductance, apoptosis, and growth control Prabha N. Ibrahim,1 Dean R. Artis,1 Gideon Bollag,1 (Francis et al., 2001). Cellular levels of cAMP and cGMP Michael V. Milburn,1 Sung-Hou Kim,2 are regulated by the relative activities of adenylyl and Joseph Schlessinger,3 and Kam Y.J. Zhang1,* guanylyl cyclases, which synthesize these cyclic nucleo- 1Plexxikon, Inc. tides, and by PDEs, which hydrolyze them into 5Ј-nucle- 91 Bolivar Drive otide monophosphates. By blocking phosphodiester hy- Berkeley, California 94710 drolysis, PDE inhibition results in higher levels of cyclic 2 Department of Chemistry nucleotides. Therefore, PDE inhibitors may have consid- University of California, Berkeley erable therapeutic utility as anti-inflammatory agents, Berkeley, California 94720 antiasthmatics, vasodilators, smooth muscle relaxants, 3 Department of Pharmacology cardiotonic agents, antidepressants, antithrombotics, Yale University School of Medicine and agents for improving memory and other cognitive 333 Cedar Street functions (Corbin and Francis, 2002; Rotella, 2002; Sou- New Haven, Connecticut 06520 ness et al., 2000). Of the 11 classes of human cyclic nucleotide phos- phodiesterases, the PDE4 family of enzymes is selective Summary for cAMP, while the PDE5 enzyme is selective for cGMP (Beavo and Brunton, 2002; Conti, 2000; Mehats et al., Phosphodiesterases (PDEs) comprise a large family 2002).
    [Show full text]
  • Phosphodiesterase Type 4 Inhibitor Suppresses Expression of Anti
    Leukemia (2001) 15, 1564–1571 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis B Siegmund1, J Welsch1, F Loher1, G Meinhardt2, B Emmerich2, S Endres1 and A Eigler1 1Division of Clinical Pharmacology and 2Division of Haematology and Oncology, Medizinische Klinik Innenstadt, Klinikum of the Ludwig- Maximilians-University Munich, Munich, Germany B cell chronic lymphocytic leukemia (B-CLL) is an incurable synergizes with chlorambucil in vitro and a phase II clinical clonal disease which shows initial responsiveness to a number trial suggested that this synergism may be clinically rel- of chemotherapeutic drugs. However, in most patients the dis- 13,14 ease becomes resistant to treatment. Rolipram, a specific evant. However, therapy with broad-spectrum PDE inhibi- inhibitor of phosphodiesterase (PDE) type 4, the PDE predomi- tors such as theophylline or pentoxifylline in patients with B- nantly expressed in B-CLL cells, has been shown to induce CLL is limited due to side-effects partially mediated by their cAMP-dependent apoptosis in these cells. In the present study, activity as adenosine receptor antagonists.15 The expression of we demonstrate that the extent of rolipram-induced apoptosis specific phosphodiesterases in B-CLL cells favors a more tar- is similar to fludarabine-induced apoptosis in vitro. The combi- geted strategy by using specific PDE inhibitors. Kim and nation of rolipram and fludarabine results in an enhancement 16 in the number of apoptotic cells compared to apoptosis Lerner described recently that CLL cells contain transcripts induced by either agent alone.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]